Siqi Liu

机构：BGI Group (China), Jinggangshan University, University of St Andrews, Chinese Academy of Medical Sciences & Peking Union Medical College, University of Malaya, Panzhihua Central Hospital, Yangzhou Vocational University, Jilin Agricultural University, Huaiyin Institute of Technology, Yangzhou University · ORCID：0000-0002-8097-3042

发表论文 74 篇 · 总被引 944 次 · h-index 18

代表论文

• π-HuB: the proteomic navigator of the human body (2024 · Nature · 被引 53)
• A novel pectin-like polysaccharide from Crocus sativus targets Galectin-3 to inhibit hepatic stellate cells activation and liver fibrosis (2024 · Carbohydrate Polymers · 被引 25)
• Selective translational control by PABPC1 phase separation regulates blast crisis and therapy resistance in chronic myeloid leukaemia (2025 · Nature Cell Biology · 被引 16)
• The value relevance of US firms’ mandated financial risk disclosures attributable to the impact of climate change (2024 · Journal of Sustainable Finance and Accounting · 被引 13)
• Heterogeneity of financial toxicity and associated risk factors for older cancer survivors in China (2023 · iScience · 被引 11)
• Subcellular RNA distribution and its change during human embryonic stem cell differentiation (2023 · Stem Cell Reports · 被引 9)